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Summary
Given the role of the EGFR/HER2 family of tyrosine kinases in breast cancer, we dissected the molecular basis of EGFR/
HER2 kinase signaling in prostate cancer. Using the small molecule dual EGFR/HER2 inhibitor PKI-166, we show that the
biologic effects of EGFR/HER-2 pathway inhibition are caused by reduced AR transcriptional activity. Additional genetic
and pharmacologic experiments show that this modulation of AR function is mediated by the HER2/ERBB3 pathway, not
by EGFR. This HER2/ERBB3 signal stabilizes AR protein levels and optimizes binding of AR to promoter/enhancer regions
of androgen-regulated genes. Surprisingly, the downstream signaling pathway responsible for these effects appears to
involve kinases other than Akt. These data suggest that the HER2/ERBB3 pathway is a critical target in hormone-refractory
prostate cancer.
Introduction cancer progression. Epidermal growth factor (EGF), the natural
ligand for EGFR, is capable of inducing AR transcriptional activ-
The androgen receptor (AR) is a ligand-dependent transcription ity (Culig et al., 1994). Transforming growth factor  (TGF-),
factor which plays a central role in male sexual development another natural EGFR ligand, is frequently coexpressed with its
and differentiation. In addition to this physiologic function, AR receptor in hormone-refractory but not hormone-naı¨ve prostate
plays a prominent role in the pathogenesis of human prostate cancer, indicative of an autocrine growth-stimulatory loop
cancer. Carcinoma of the prostate is the most common malig- (Scher et al., 1995). Forced overexpression of the HER2 kinase
nancy affecting males in the U.S. Up to 30% of patients develop in prostate cancer cells enhances AR function and hormone-
metastatic disease and receive treatment with GnRH analogs independent growth (Craft et al., 1999; Yeh et al., 1999). The
and AR antagonists to block the action of testicular and adrenal relevance of this latter finding has been questioned by the sub-
sequent examination of clinical samples. While some of theseandrogens. This “androgen ablation therapy” effectively inhibits
tumor cell growth for a variable period of time but is universally studies report a trend toward higher HER2 levels in hormone-
refractory prostate cancer (Osman et al., 2001; Shi et al., 2001;followed by tumor regrowth despite castrate levels of andro-
gens. This latter “hormone-refractory” state of the disease is Signoretti et al., 2000), others have found no increase in HER2
gene copy number or HER2 protein in hormone-refractory dis-characterized by expression of the androgen receptor (AR) and
AR-regulated genes such as prostate specific antigen (PSA), ease (Calvo et al., 2003; Savinainen et al., 2002). This contrasts
to human breast cancer, where HER2 kinase activation hassuggesting that the AR pathway is reactivated (Isaacs and
Isaacs, 2004). been shown to be biologically relevant and results from gene
amplification and HER2 protein overexpression (Slamon et al.,Several lines of evidence have implicated the epidermal
growth factor receptor (EGFR, also known as ERBB1) and its 1987). The disappointing activity of the EGFR inhibitor Gefitinib
in recent prostate cancer trials (Blackledge, 2003) has furtherdimerization partner HER2 (also known as ERBB2) in prostate
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challenged the role of the EGFR/HER2 axis in hormone-refrac- elements (AREs). In cell lines expressing either endogenous
(LAPC4, LNCaP) or transfected (COS-7) AR, pretreatment withtory prostate cancer, and reinforces the need to understand in
greater molecular detail how ERBB kinase signals modulate PKI-166 (5 M) impaired AR activation by the synthetic andro-
gen R1881, and the degree of inhibition was invariably greatestandrogen receptor function.
Kinase pathways have been implicated as modulators of at R1881 concentrations between 0.1 and 1 nM (Figure 1A).
Since transcriptional activity of nuclear hormone receptorsnuclear hormone receptor function (Shao and Lazar, 1999). In
some instances, the substrates of these phosphorylation signals is dependent on a specific promoter context, we extended the
determination of AR activity from artificial promoters to the en-have been identified. Regulation of estrogen receptor (ER) func-
tion by MAPK, for example, occurs through phosphorylation dogenous androgen regulated gene prostate-specific androgen
(PSA). Similar to our reporter gene assays, the effect of PKI-of the receptor itself (Kato et al., 1995), as well as through
phosphorylation of the p160 nuclear receptor coactivators AIB1 166 on PSA expression in LAPC4 cells was maximal between
0.1 and 1 nM R1881 (Figure 1B, upper panel). Inhibition of PSA(Font de Mora and Brown, 2000) and TIF-2 (Lopez et al., 2001).
The mechanisms through which kinase signals modulate AR expression by PKI-166 was also observed in human prostate
cancer xenografts growing subcutaneously in SCID mice. Sincefunction are currently unknown. In analogy to the estrogen re-
ceptor, TIF-2 phosphorylation by MAPK has been shown to mice do not express PSA, the ratio between serum PSA and
tumor volume (“PSA index”) approximates AR activity in themediate effects of EGF on AR function in transfection experi-
ments (Gregory et al., 2004). Direct phosphorylation by MAPK implanted tumors (Gleave et al., 1992). Treatment of mice for
two weeks with PKI-166 reduced the PSA index in female andof purified AR peptides has been observed in vitro (Yeh et al.,
1999), but could not be confirmed in a subsequent mass spec- castrated male mice, but not in castrated male mice receiving
dihydrotestosterone replacement (Figure 1B, lower panel).trometric analysis of AR phosphorylation (Gioeli et al., 2002).
Perhaps more importantly, it remains uncertain whether the To examine the interplay between androgen receptor and
ERBB RTKs in nonmalignant tissue, we examined the effectsEGFR/HER2-MAPK axis is a biologically relevant modulator of
AR function. of PKI-166 on the development of male murine urogenital tissue.
Daily treatment with PKI-166 was initiated at the beginning ofIn this study, we dissect the crosstalk between ERBB RTKs
and AR function using a dual EGFR/HER2 kinase inhibitor with the growth spurt for prostate and seminal vesicles (postnatal
day 20) (McKinney and Desjardins, 1973) and continued for twopreviously documented hormone-dependent bioactivity (Mel-
linghoff et al., 2002). Our results show that ERBB kinase signals weeks. Compared to vehicle treated littermate controls, the wet
weight of prostate/seminal vesicles from PKI-166 treated miceare required for optimal AR function at physiologically low an-
drogen concentrations. RNA interference experiments show was reduced by approximately 35%. Exogenous androgen sup-
plementation during the period of PKI-166 treatment rescuedthat these signals are not mediated through EGFR, but rather
through the association of HER2 with other members of the the effect of PKI-166 on the growth of prostate/seminal vesicle
(Figure 1C). Prostatic epithelial differentiation was not affectedERBB receptor family. Optimization of AR function through
HER2 occurs through increased AR binding to its cognate DNA by PKI-166 and overall gland morphology appeared normal
(data not shown). This antiandrogen-like effect of PKI-166 wastarget regions and through protection of AR from ubiquitin-
mediated degradation. Surprisingly, the downstream kinase re- not due to endocrine effects, as serum testosterone levels were
unaffected by PKI-166 (Figure 1C, insert). This phenotype wassponsible for these AR effects appears to be distinct from Akt.
Our findings provide novel insights into AR function and suggest reminiscent of the impaired growth of fetal urogenital sinuses
from IGF-I and from IGF-R1 knockout mice grafted beneath thethat successful application of ERBB kinase family inhibitors in
hormone-refractory prostate cancer may require specific tar- renal capsule of athymic mice (Hayward and Cunha, 2000). In
summary, these results indicate that ERBB-mediated signalsgeting of the HER2/ERBB3 heterodimer complex.
contribute to AR function in malignant and nonmalignant tissue,
and that this contribution is greatest when the androgen concen-Results
trations are not saturating.
ERBB kinase activity is required for full AR function
We previously reported that androgen modulates the ability of The antiandrogen properties of PKI-166 are explained
by HER2, not EGFR inhibitionthe ERBB-selective kinase inhibitor PKI-166 (Traxler et al., 2001)
to inhibit prostate cancer growth in vivo. While tumors growing The ERBB receptor kinases includes four family members:
EGFR, HER2, ERBB3, and ERBB4. Despite the lack of a naturalin castrate male animals were particularly sensitive to ERBB
RTK inhibition, this sensitivity was lost following androgen sup- ligand, HER2 plays a prominent role within the ERBB signaling
network as a preferred heterodimerization partner for other li-plementation (Mellinghoff et al., 2002). This observation raised
the question whether ERBB RTKs support prostate cancer gand-bound ERBBs (Olayioye et al., 2000). As a first approxima-
tion to define this signaling network in prostate cancer, wegrowth through regulation of the AR pathway. To address this
question, we defined the contribution of ERBB signals to AR analyzed ERBB gene expression profiles of seven human pros-
tate cancer xenografts (Figure 2A, left panel). In this group offunction over a wide range of androgen concentrations. These
concentrations were chosen to represent not only androgen samples, normalized RNA expression of HER2 (mean  SEM
2.74  0.23) and ERBB3 (1.83  0.32) was significantly higherlevels found in adult healthy men, but also reduced concentra-
tions measured in human prostate cancer tissue in the setting than expression of EGFR (0.78  0.17) and ERBB4 (0.09 
0.08). Relative levels of ERBB gene expression in these xeno-of androgen ablation therapy (Mohler et al., 2004).
In our first set of experiments, AR function was measured graft tumors correlated closely with relative levels of ERBB pro-
tein expression in the prostate cancer cell lines derived fromusing a transiently transfected luciferase reporter gene driven
by an artificial promoter containing four androgen response these xenografts (Figure 2A, right panel).
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Figure 1. PKI-166 inhibits androgen receptor function
A: Effect of PKI-166 on AR reporter gene activity. Increasing amounts of the synthetic androgen R1881 were added to cells transfected with the AR reporter
gene 4xARE-luciferase in the presence or absence of the dual EGFR/HER2 kinase inhibitor PKI-166. LAPC4 cells express endogenous AR; COS-7 cells were
cotransfected with pCMV-AR. The right panel shows % mean inhibition of AR-reporter activity by PKI-166 in the prostate cancer cell lines LAPC4 and LNCaP.
B: Effect of PKI-166 on protein expression of the endogenous androgen-regulated gene prostate specific antigen (PSA). Upper panel: increasing amounts
of R1881 were added to LAPC4 cells growing in hormone-depleted media, and PSA induction was determined after three days by immunoblotting of
whole cell lysates. Lower panel: SCID mice bearing established subcutaneous human prostate cancer xenografts were treated for two weeks with PKI-166
(100 mg/kg) or vehicle. The PSA index was determined as ratio between tumor volume and serum PSA measured by ELISA. PKI-166 was administered daily
by gavage, and Dihydrotestosterone (DHT) was administered as slow-release pellets.
C: Effect of PKI-166 on development of the male urogenital system in FVB inbred mice. Intact male mice were treated with PKI-166 (100 mg/kg) or vehicle
between postnatal day 20 and 34. Dihydrotestosterone (DHT) was administered as slow-release pellets. At the end of the experiment, the male urogenital
tract (P: prostate, SV: seminal vesicle, B: bladder) was photographed in situ. Shown are the wet weights (mean  SD) from PKI-166 treated mice compared
to vehicle-treated mice (n  6 per group). Inset, serum testosterone levels (mean  SD) in six adult male mice before and during treatment with PKI-166.
Although PKI-166 is known primarily as an EGFR inhibitor To determine whether EGFR is required to mediate the effect
of ERBB kinase inhibitors on AR function, we performed AR(Mendelsohn, 2001), it has activity against HER2 at 10-fold
higher concentrations (Holbro et al., 2003; Traxler et al., 2001). reporter assays in a 3T3 subline which does not express func-
tional EGFR (Pruss and Herschman, 1977). Inhibition of AR func-We previously demonstrated (Mellinghoff et al., 2002) that both
kinases are inhibited by the doses used in all of the experiments tion by PKI-166 in these cells was very similar in magnitude
(Figure 2C) to inhibition of AR function in EGFR-expressing cellsperformed in Figure 1. To dissect which members of the ERBB
signaling network contribute to AR function, we employed three (Figure 1A). These experiments suggested that HER2, but not
EGFR, contributes to AR function at low androgen levels. Toapproaches: (1) drugs with a wider differential in the inhibitory
concentrations (IC50s) required to block EGFR and HER2 RTK obtain genetic evidence for this model, we used RNA interfer-
ence to transiently and selectively knock down expression levelsactivity, (2) an EGFR-negative cell line, and (3) genetic silencing
of individual ERBB family members using RNA interference. The of either EGFR and/or HER2. This analysis was performed in
three different cell lines (Figure 2D) using two different targetquinazoline PD153035 (Fry et al., 1994) is an EGFR kinase inhibitor
that also inhibits the HER2 kinase, but only at 100-fold higher sequences for each gene (Supplemental Figure S1A) to minimize
gene nonspecific effects of interfering RNAs (Moss and Taylor,drug concentrations than the EGFR RTK. At drug concentrations
that completely inhibit the EGFR RTK, PD153035 had no effect 2003). EGFR knockdown had no significant effect on AR activity,
whereas genetic silencing of HER2 by RNA interference mirroredon R1881-induced AR function. A marked reduction of AR func-
tion, however, was noted at drug concentrations which also the effect of PKI-166 (Figure 2D). Control experiments estab-
lished that the RNAi silencing was specific for each ERBB kinaseinhibit HER2 (Figure 2B). This data indicates that EGFR RTK
inhibition is not sufficient to impair AR function. isoform (Supplemental Figure S1A). In summary, these experi-
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Figure 2. The HER2 kinase, not EGFR, is critical for AR function
A: Expression of ERBB receptors in human prostate cancer. Left panel: normalized RNA expression values for ERBB receptor family members (EGFR, HER2,
ERBB3, ERBB4) in seven human prostate cancer xenograft tumors (LNCaP, LAPC4, LAPC9, CWR22, LUCaP23, LUCaP35, LUCap41). Right panel: ERBB protein
expression levels in the prostate cancer cell lines LNCaP and LAPC4. Whole cell lysates from A431 and T47D cells were loaded as positive controls for the
EGFR and ERBB4 antibodies, respectively.
B: Effect of the EGFR-selective small molecule kinase inhibitor PD153035 on R1881-induced AR reporter gene activity (4xARE-Lux) in COS-7 cells. Inset: IC50s
for inhibition of EGFR and HER2 autophosphorylation by PD153035 as determined by phosphotyrosine immunoblotting in A431 (EGFR) and SKBR3 (HER2)
cells.
C: Effect of PKI-166 on AR reporter gene activity (4xARE-Lux) in EGFR negative 3T3 cells.
D: Effect of isoform-specific siRNAs against EGFR and HER2 on ligand-induced AR reporter gene activity in the three cell lines, COS-7, LNCaP, and LAPC4.
Results are representative for RNAis targeting two different sequences of EGFR and HER2.
ments indicated that the HER2 kinase is the relevant target of through the HER2/ERBB3 axis. These data do not exclude a
more general role for EGFR in prostate cancer growth, particu-PKI-166 in terms of AR regulation. In contrast, EGFR plays a
minor, if any, role. larly since EGFR expression levels in these two cell line models
(LNCaP and LAPC4) are lower than in other prostate cancerTo further validate the significance of the HER2 kinase for AR
function and prostate cancer growth, we examined the effects of models (Figure 2A).
stable HER2 RNAi knockdown on growth and AR function in
human prostate cancer cell lines. As predicted by our results Regulation of AR function through Akt-dependent
and -independent signalswith PKI-166, knockdown of HER2 resulted in impaired growth
(Figure 3A) and AR activity (Figure 3B). Importantly, the growth Since HER2/ERBB3 and HER2/ERBB4 heterodimers signal pri-
marily through the PI3Kinase (PI3K) pathway (Carraway et al.,inhibitory effects of HER2 knockdown could be rescued by
raising the concentration of R1881 from 0.5 to 5 nM (Figure 1995), we examined in greater detail the role of this pathway
for AR function. Previous studies have yielded controversial3C). Since HER2 is an orphan receptor and recruits other ERBB
family members as part of its activation platform, we reasoned results as to whether the serine/threonine kinase Akt, a main
effector of the PI3K pathway, enhances (Wen et al., 2000; Linthat PKI-166 must inhibit signals originating from HER2/ERBB3
and/or HER2/ERBB4 heterodimers. Indeed, treatment of LNCaP et al., 2003; Nan et al., 2003) or impairs (Lin et al., 2001, 2002,
2003) AR function and stability. Akt has been suggested toand LAPC4 cells with the ERBB3/ERBB4 ligand heregulin-1
resulted in PKI-166 reversible tyrosine phosphorylation of pro- directly phosphorylate AR at the Serine 213 and Serine 791
(Wen et al., 2000; Lin et al., 2001), but no evidence for phosphor-teins of about 180 kDa (Figure 3D), representing phosphorylated
ERBB2 and ERBB3 (Sliwkowski et al., 1994; Holbro et al., 2003). ylation at these sites was seen by mass spectrometric examina-
tion (Gioeli et al., 2002; Wong et al., 2004).In summary, these results suggest that the effects of PKI-166
on AR function are EGFR-independent and may be mediated Inhibition of the lipid kinase PI3K with LY294002 (12.5 M)
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Figure 3. HER2 kinase regulates prostate cancer
growth through its effects on AR function
A: Effect of HER2-specific hairpin RNAi on growth
of LNCaP and LAPC4 cells. Cells were grown in
charcoal stripped (CS) media supplemented
with 0.5 nM R1881 and counted in quadruplets.
Right panel, HER2 immunoblot of whole cell ly-
sates from each cell line. STAT-1 was used as
loading control.
B: Effect of HER2-specific hairpin RNAi on PSA
production of LNCaP cells. PSA concentration
was determined in the supernatatant of LNCaP
cells growing in CS media supplemented with
0.5 nM R1881. PSA values were normalized per
cell number.
C: Growth of LNCaP-HER2 RNAi cells and LNCaP-
control RNAi cells in CS media supplemented
with either 0.5 or 5 nM R1881.
D: Phosphotyrosine immunoblot of LNCaP and
LAPC4 cells stimulated for 30 min with Heregu-
lin -1 (50 ng/ml) in the presence or absence of
PKI-166.
impaired the induction of AR function by 0.1 nM R1881 to a lated in response to ligand, we observed a consistent reduction
in AR phosphorylation at this residue when cells were treatedsimilar degree as PKI-166 (Figure 4A, left panel). Genetic inhibi-
tion of PI3K signaling by overexpression of the phosphatase with PKI-166 (Figure 4D). Interestingly, this effect of PKI-166
was less pronounced at higher R1881 concentrations, correlat-PTEN similarly impaired AR function and lowered AR protein
levels (Figure 4A, right panel). Overexpression of a constitutively ing with the dose-dependent effects of androgen on the ability
of PKI-166 to modulate AR function (Figure 1A). This observationactive, myristoylated Akt (myr-Akt) allele in LAPC4 prostate can-
cer cells markedly raised AR protein levels and PSA production establishes that AR is a substrate of this HER2 regulated kinase
pathway. The identity of the direct AR kinase is unknown, butin vitro and in vivo (Figure 4B). In summary, these experiments
validate the PI3K/Akt signaling axis as an important positive appears unlikely to be Akt, since amino acids surrounding Serine
81 do not resemble an Akt consensus site.regulator of AR function and stability.
We next asked whether the effects of PKI-166 on AR func-
tion, demonstrated above to be HER2/ERBB3-dependent, are HER2 kinase stabilizes androgen receptor protein
Kinase pathways have been shown to modulate all aspects ofmediated through Akt. Surprisingly, overexpression of myr-Akt
in LAPC4 cells could not rescue the inhibitory effects of PKI- nuclear hormone receptor function (Shao and Lazar, 1999). To
identify the mechanism of AR regulation by HER2, we examined166 on AR protein levels and PSA production (Figure 4C, upper
panel). Similar results were observed in an isogenic 3T3 cell the effects of PKI-166 on AR ligand binding using saturation
binding assays. This is a critical first experiment, because inter-line pair stably expressing vector control versus myr-Akt and
transiently transfected with AR and an androgen-dependent ference with ligand binding would be the simplest explanation
for the effects of PKI-166 on R1881-induced AR phosphoryla-reporter construct (data not shown). Immunoblots using a phos-
pho-Akt antibody showed that PKI-166 has no effect on phos- tion shown above in Figure 4D. However, in both LAPC4 and
LNCaP prostate cancer cells, PKI-166 pretreatment only mod-pho-Akt levels in myr-Akt-expressing cells (Figure 4C, lower
panel), ruling out the possibility that this failure to rescue is due estly reduced the high binding affinity of AR (Supplemental Fig-
ure S2A). We next asked whether HER2 kinase inhibition im-to direct inhibition of Akt. Since myr-Akt may not replace all the
functions of endogenously activated Akt, it remains possible paired ligand-induced translocation of AR from the cytosolic to
the nuclear compartment. In the absence of ligand, AR wasthat Akt plays a role in the HER2/ERBB3 signal to AR.
We next addressed whether AR itself is a substrate in the predominantly found in the cytoplasm using both immunofluo-
rescence and cell fractionation assays. Treatment with 1 nMkinase pathway modulated by PKI-166. Based on sequence
analysis for kinase consensus motifs (Blom et al., 1999), the R1881 resulted in translocation of AR to the nuclear compart-
ment within 60 min and was not affected by treatment with PKI-androgen receptor contains over 40 predicted phosphorylation
sites. Seven of these sites have been shown to be phosphory- 166 (Supplemental Figure S2B).
During our cell fractionation experiments, we observed de-lated in a recent mass spectrometric analysis of AR (Gioeli et
al., 2002). Using a commercially available phosphospecific anti- creased AR protein levels in both nuclear and cytosolic compart-
ments at later time points (72 hr). We therefore examined thebody to Serine 81, one of the sites most intensely phosphory-
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Figure 4. Role of the PI3Kinase/Akt pathway in AR function
A: Left panel: effect of the PI3K inhibitor LY294002 on AR function. COS-7 cells transiently transfected with 4xARE-Luc, pCMV-AR, and renilla-luciferase were
treated for 30 min with LY294002 or PKI-166 prior to induction with 0.1 nM R1881. Right panel: effect of the phosphatase PTEN on AR function. COS-7 cells
were transfected with 4xARE-Luc, pCMV-AR, renilla-luciferase, and pSR or pSR-PTEN and reporter activity induced with 0.1 nM R1881. Immunoblots show
AR levels in lysates from one representative sample for each reporter assay triplicate.
B: Left panel: expression of AR and PSA in parental LAPC4 cells and an isogenic subline expressing myristoylated Akt (myr-Akt). Cells were grown in CS
media supplemented with vehicle or 1 nM R1881 for 36 hr prior to lysis and immunoblotting. Right panel: expression of AR and Akt in parental LAPC4 cells
and myr-Akt LAPC4 cells growing as xenograft tumors in intact male SCID mice.
C: Upper panel: LAPC4 cells growing in CS media supplemented with 0.5 nM R1881 were treated with PKI-166 for 72 hr. AR levels were determined by
immunoblotting of whole cell lysates. PSA values reflect secreted PSA (measured by ELISA) per cell. Lower panel: effect of PKI-166 on wild-type endogenous
Akt, myr-Akt, and overexpressed wild-type Akt in stable 3T3 sublines. Cells were lysed 6 hr after addition of PKI-166 or vehicle.
D: PKI-166 impairs R1881-induced phosphorylation of AR at Ser81. LNCaP cells and COS-7 cells transfected with pCMV-AR were treated with PKI-166 for 30
min prior to induction with R1881. Cells were lysed 6 hr after R1881-induction and probed with a phosphospecific antibody for AR-Ser81.
effects of HER2 kinase inhibition on AR protein levels in greater of the androgen receptor (Figure 5C, top panel). Similar to other
steroid hormone receptors (Nawaz et al., 1999a; Lange et al.,detail in whole cell lysates. Treatment of LAPC4 cells for three
days with the synthetic androgen R1881 led to a dose-depen- 2000), AR is a substrate of the ubiquitin-proteasome pathway
(Sheflin et al., 2000). Cotransfection of AR with HA-epitope-dent increase in AR protein levels (Figure 5A, upper panel),
consistent with ligand-induced receptor stabilization (Kemp- tagged ubiquitin into COS-7 cells confirmed that AR is, indeed,
ubiquitinated, and that the degree of ubiquitination is greatestpainen et al., 1992). Simultaneous treatment with PKI-166 mark-
edly reduced AR levels at nonsaturating androgen concentra- at low androgen concentrations and enhanced by treatment
with PKI-166 (Figure 5C, middle panel). In summary, these datations. The effect of PKI-166 on AR protein levels was also
observed in three breast cancer cell lines expressing endoge- indicate that AR protein levels are regulated by a HER2/ERBB3
kinase signal. Consistent with this model, cotransfection ofnous wild-type AR (Figure 5A, lower panel), suggesting a more
general phenomenon of AR regulation. HER2, but not EGFR, raised the levels of AR transiently trans-
fected into COS-7 cells (Figure 5D).We next asked whether the effect of PKI-166 on AR protein
levels resulted from decreased AR transcription or destabiliza-
tion of the receptor protein. Using quantitative RT-PCR, we HER2 enhances binding of AR to AREs
in androgen-responsive genesfound no effect of PKI-166 on AR transcript levels, whereas
PSA transcript levels were markedly reduced (Figure 5B). These If modulation of AR protein levels is the primary mechanism by
which the HER2/ERBB3 axis regulates AR function, we hypothe-results indicate that regulation of AR levels by HER2 occurs at
a posttranscriptional level. Pulse-chase experiments confirmed sized that forced elevation of AR levels should rescue the effect
of PKI-166 on AR function. We tested this hypothesis using twothat inhibition of HER2 by PKI-166 accelerated the degradation
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Figure 5. HER2 kinase stabilizes AR protein levels
A: Effect of PKI-166 on AR protein levels. Upper panel: immunoblot analysis of LAPC4 prostate cancer cells treated for two days with increasing concentrations
of R1881 in the presence or absence of PKI-166. Lower panel: immunoblot analysis of three breast cancer cell lines (MCF7, T47D, BT474) growing for two
days in CS media in the presence or absence of PKI-166.
B: Semiquantitative RT-PCR analysis for AR, PSA, and GAPDH mRNA in LAPC4 cells treated for two days with R1881 in the presence or absence of PKI-166.
C: Upper panel: pulse-chase analysis of androgen receptor stability in COS-7 cells transfected with pCMV-AR. Lower panel, left: COS-7 cells were transfected
with pCMV-AR and HA-tagged ubiquitin and treated with R1881 for 36 hr. Anti-AR immunoprecipitates from whole cell lysates were probed with anti-HA
and anti-AR antibodies. Lower panel, right: COS-7 cells were transfected with pCMV-AR and treated with PKI-166 for three or six hours. Whole cell lysates
were subjected to anti-AR immunoprecipitation followed by immunoblotting with a polyclonal anti-ubiquitin antibody.
D: COS-7 cells were transfected with pCMV-AR and expression vectors for EGFR or HER2 for 36 hr and AR levels determined by immunoblotting in whole
cell lysates.
different approaches: (1) inhibition of proteasomal AR degrada- ments, because they contain several AREs in the promoter and
tion using the proteasome inhibitor lactacystin (Fenteany and enhancer regions (Cleutjens et al., 1996, 1997; Mitchell et al.,
Schreiber, 1998), and (2) forced overexpression of AR by lentivi- 2000). As previously reported, treatment of LNCaP cells with
ral expression. Pretreatment of COS-7 cells with lactacystin R1881 resulted in rapid recruitment of AR to the PSA enhancer
rescued the effects of PKI-166 on AR protein levels (Figure 6A, region (Louie et al., 2003; Shang et al., 2002) (Figure 6B). Recruit-
upper panel), supporting the notion that HER2 stabilizes AR ment to the PSA-promoter was only marginally induced by 0.1
protein levels by protecting it from ubiquitin-mediated degrada- nM R1881. AR recruitment to the PSA enhancer was almost
tion. This increase in AR protein levels, however, was not suffi- completely blocked by pretreatment with PKI-166. Identical re-
cient to restore AR function in the presence of PKI-166 (Figure sults were obtained when AR recruitment to the KLK-2 enhancer
6A, lane 8 versus lane 4). Similar to our lactacystin experiment,
was examined. Recruitment of RNA polymerase II to the gene
forced overexpression of AR by lentiviral infection was not suffi-
regulatory region of the PSA and KLK-2 genes correspondedcient to rescue the inhibitory effects of PKI-166 on AR function
closely with AR binding, suggesting that recruitment of AR is(Figure 6B, lower panel). In summary, these results suggest that
the rate-limiting step in assembly of a functional transcriptionthe HER2/ERBB3 axis regulates AR function through additional
complex. Of note, chromatin immunoprecipitation experimentsmechanisms beyond protein stabilization.
were performed within 1 hr of PKI-166 exposure, prior to anySince regulation of DNA binding by phosphorylation has
measurable effects on AR protein levels.been documented for various transcription factors (Yamamoto
Since our biological and transcriptional experiments showedet al., 1988; Prywes et al., 1988), we examined ligand-induced
that saturating levels of androgen rescue the effects of HER2recruitment of AR to its cognate DNA target sequences (“AREs”
inhibition on AR function, we predicted that androgen shouldor androgen-response elements) using chromatin immunopre-
also rescue the effect on DNA binding. Indeed, when R1881cipitation. The 5-regulatory regions of the PSA and KLK-2
genes were chosen as DNA target sequences for these experi- concentrations were raised from 0.1 nM to 10 nM, PKI-166 no
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Figure 6. PKI-166 impairs binding of AR to cog-
nate DNA target sequences
A: Upper panel: concurrent analysis of AR re-
porter gene activity (4xARE-Lux) and AR protein
levels in lysates from transfected COS-7 cells
treated with PKI-166 in the presence or absence
of the proteasome inhibitor lactacystin. Pretreat-
ment with lactacystin started six hours prior to
addition of PKI-166. Lower panel: LAPC4 cells sta-
bly expressing CSCG-vector or CSCG-AR were
transfected with 4xARE-Luc and renilla luciferase
and treated with PKI-166 or vehicle prior to induc-
tion with 0.1 nM R1881.
B: Chromatin immunoprecipitation of AR and
RNA polymerase II (Pol II) in LNCaP cells treated
for one hour with 0.1 nM R1881 in the presence or
absence of PKI-166. Linearity of the amplification
reaction was monitored by using three different
volumes (1, 2, 4) of input DNA from vehicle-
treated samples. Shown is DNA occupancy at
the PSA promoter, PSA enhancer, and KLK-2 en-
hancer.
C: Chromatin immunoprecipitation analysis of
AR recruitment to the PSA enhancer in LNCaP
cells treated for 60 min with R1881 in the pres-
ence or absence of PKI-166.
longer impaired the immediate androgen-induced recruitment phosphorylation at this residue (Gioeli et al., 2002). Furthermore,
mutagenesis studies at this site (AR S81A), at first glance, failedto the PSA enhancer (Figure 6C).
to phenocopy the biologic effects of PKI-166 treatment. Collec-
tively, these data suggest a complex mode of AR regulation byDiscussion
one or more kinases downstream of HER2/ERBB3. Our recon-
stitution studies with Akt, which fail to rescue the effects of PKI-In this study, we have defined a HER2-dependent signal that
166 on AR function, cast some doubt as to whether the PI3K/is critical for AR function at low androgen concentrations. Our
Akt pathway is the effector of this signal.finding that this signal is EGFR-independent shifts the emphasis
Besides the androgen receptor itself, other members of thefrom the EGFR/HER2-MAPK axis to the HER2/ERBB3 axis. Fur-
AR signaling pathway may be substrates of HER2/ERBB3-regu-ther support for a role of the HER2/ERBB3 axis in hormone-
lated kinase signals. There is ample precedent for phosphoryla-refractory prostate cancer stems from recent preclinical studies.
tion of steroid hormone receptor coactivators and corepressorsInterruption of HER2/ERBB3 heterodimerization using the
(Font de Mora and Brown, 2000; Janknecht and Nordheim,monoclonal antibody 2C4 potently inhibited the growth of hor-
1996; Hong and Privalsky, 2000; Lopez et al., 2001; Rowan et al.,mone-refractory prostate cancer xenografts (Agus et al., 2002),
2000). To date, MEK-Erk kinases have been tightly implicated inwhereas Trastuzumab, which does not block HER2/ERBB3 di-
modulating coregulator function, but there is no knowledgemerization, had minimal activity (Agus et al., 1999). Our data
about such regulation by PI3K-related pathways. Further experi-showing that HER2 but not EGFR is responsible for this AR
ments are required to determine if HER2/ERBB3 signals cansignal suggests that pathways unique to the HER2/ERBB3 het-
affect AR function through phosphorylation of coregulators.erodimer (PI3K, Akt, others) are more likely mediators than Raf/
We defined two properties of AR regulation by the HER2MEK/Erk. This conclusion is further supported by the analogous
kinase, DNA binding and protein stability (Figure 7). There areeffects of PI3K inhibitors on AR function.
a number of examples in the hormone receptor field showingThe precise details of how the HER2/ERBB3 kinase pathway
regulation of DNA binding by phosphorylation (Arnold and No-modulates AR function remain to be elucidated. We currently
tides, 1995; Bhat et al., 1994; Chen et al., 1999; Denner et al.,favor a model in which AR is a substrate of a HER2-regulated
1989; Katz et al., 1995; Rangarajan et al., 1992; Tzagarakis-kinase cascade. The strongest evidence in favor of this model
is PKI-166-reversible phosphorylation of AR at Serine 81 in Foster and Privalsky, 1998; Sugawara et al., 1994; Hirata et al.,
1993). Further experiments will determine whether the effect ofresponse to androgen. Modulation of phosphorylation at this
site correlates precisely with the effects of PKI-166 on AR stabil- HER2 on DNA binding is due to effects on AR dimerization,
increased dissociation of heat-shock proteins with unmasking ofity and transcriptional activity as well as rescue by higher con-
centrations of R1881. Much more work is needed to define the DNA binding sites, and/or altered assembly with coactivator
proteins which stabilize the formation of the AR transcriptionthe kinase directly responsible for AR phosphorylation at this
residue, and whether AR Serine 81 is solely responsible for complex. There is also increasing evidence for a role of the
ubiquitin-proteasome degradation system in transcriptional reg-these effects. Serine81 occurs in the context of a Protein Kinase
C consensus site; however, PKC inhibitors failed to impair AR ulation (Lipford and Deshaies, 2003). The ubiquitin-ligase E-6
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after transfection and 30 min prior to addition of R1881. Luciferase activity
was assayed in triplicates 36 hr after transfection. To control for general
effects on transcription, constitutive expression plasmids for -galactosi-
dase or renilla luciferase were cotransfected in all reporter assays and Lucif-
erase values represent ratios of firefly luciferase/-galactosidase or firefly
luciferase/renilla luciferase.
Animal experiments
Mice were maintained in a defined colony and treated following the guidelines
of the UCLA Animal Research Committee. PKI-166 was administered daily
by gavage at a dose of 100 mg/kg. Testosterone pellets (Innovative Research
of America, Sarasota, Florida) were implanted subcutaneously.
Gene expression profiling and RT-PCR
Figure 7. Model for the dual effects of the HER2/ERBB3/PI3K signal on andro- Normalized RNA expression values for ERBB family members was surveyed
gen receptor protein stability and DNA binding in a previously described dataset generated from seven different human
prostate cancer xenograft models (Chen et al., 2004). RT-PCR was per-The HER2/ERB3 axis provides signals to AR that enhances its DNA binding
formed as previously described (Chen et al., 2004).to ARE target sequences and protect AR from proteasome-mediated deg-
radation. CoR, coregulators; PolII, RNA-Polymerase II; Ub, ubiquitin.
AR translocation, ligand binding, and stability
Immunofluorescence, cell fractionation, saturation binding, and pulse-chase
assays were performed as previously described (Dignam et al., 1983; Greg-
ory et al., 2001; Kemppainen et al., 1992).associated protein, for example, has been shown to function
as a coactivator for the steroid receptor superfamily (Nawaz et
Chromatin immunoprecipitation
al., 1999b). Whether a more complex model accounts for the LNCaP cells were grown in RPMI supplemented with 10% charcoal-stripped
effects of the Her2/ERBB3-PI3K signal on AR function will await serum for four days before each experiment. Cells were treated with vehicle
detailed mapping of kinase-dependent phosphorylation changes or PKI-166 for 10 min prior to addition of R1881 at the indicated concentra-
tions. After 60 min of stimulation with R1881, crosslinking and further pro-in all members of the AR pathway.
cessing was performed as previously published (Louie et al., 2003). Immuno-The androgen receptor has emerged as key molecular deter-
precipitated DNA was amplified by PCR for 25 cycles. To monitor the linearityminant in the progression of human prostate cancer to a hor-
of the amplification conditions, serial dilutions of control DNA were amplifiedmone-refractory state. Increased AR expression is frequently
together with the experimental samples.
observed in hormone-refractory tumors (Edwards et al., 2003)
and is sufficient to convert prostate cancer growth from a hor- RNA-interference
mone-sensitive to a hormone-refractory stage (Chen et al., Sequences for interfering RNAs (siRNA and shRNA) were 5-CTACTTGGAG
2004). Our results show that small molecule inhibitors of the GACCGTCGC-3 (EGFR RNAi #1), 5-GTGTGTAACGGAATAGGTA (EGFR
RNAi #2), 5-GATCTTTGGGAGCCTGGCA-3 (HER2 RNAi #1), and 5-ATCTERBB2 RTK potently antagonize AR function and may add to
TAGACGAAGCATACG-3 (HER2 RNAi #2). siRNAs were obtained fromcurrently available AR antagonists which are limited by their
Dharmacon, and hairpin RNAi constructs targeting HER2 were generatedpotency and partial agonism (Taplin et al., 1999; Chen et al.,
using the Clonetech pSIREN Kit.
2004). By precisely defining the kinases and phosphorylation
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